Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$161.93 USD

161.93
3,100,660

+2.84 (1.79%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $161.85 -0.08 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks.com featured highlights include: Marine Products, Illumina, Chemed, Surmodics and MAM

by Zacks Equity Research

Zacks.com featured highlights include: Marine Products, Illumina, Chemed, Surmodics and MAM

    Zacks Equity Research

    IDEXX's (IDXX) Catalyst Uptake Remains Strong & Boosts CAG

    by Zacks Equity Research

    Solid organic growth trend within IDEXX's (IDXX) CAG revenues to sustain on the back of a strong global placement of high-premium Catalyst instruments.

      Zacks Equity Research

      Abbott Presents Positive Data for AMPLATZER Amulet Device

      by Zacks Equity Research

      Abbott (ABT) proceeds with initiatives to boost the core Structural Heart division.

        Zacks Equity Research

        Abbott Presents Positive Study Results for Tendyne Device

        by Zacks Equity Research

        Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.

          Tirthankar Chakraborty headshot

          5 Top Efficient Stocks to Keep on Your Radar

          by Tirthankar Chakraborty

          We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

            Zacks Equity Research

            AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint

            by Zacks Equity Research

            AbbVie's (ABBV) phase III iLLUMINA study evaluating Imbruvica in combination with Gazyva meets its primary endpoint of improvement in progression-free survival.

              Zacks Equity Research

              Agios (AGIO) Progressing Well on Pipeline Amid Competition

              by Zacks Equity Research

              Agios (AGIO) has several interesting candidates in its pipeline. However, the company still faces stiff competition.

                Zacks Equity Research

                Myriad Genetics' Prolaris Expands on New Coverage Decisions

                by Zacks Equity Research

                This increased rate in commercial insurer coverage for Myriad Genetics' (MYGN) Prolaris comes close on the heels of the NCCN guidelines.

                  Zacks Equity Research

                  Here's Why You Should Buy Boston Scientific (BSX) Stock Now

                  by Zacks Equity Research

                  Boston Scientific's (BSX) inorganic expansion plan bodes well for operational growth.

                    Zacks Equity Research

                    Why is Illumina (ILMN) Up 13.5% Since Its Last Earnings Report?

                    by Zacks Equity Research

                    Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.